Graham JB, Earnshaw SR, Castelli-Haley J, Oleen-Burkey M, Johnson KP. Cost-effectiveness of glatiramer acetate and natalizumab in relapsing-remitting multiple sclerosis in the presence of long-term clinical evidence. Poster presented at the 2007 ISPOR 10th Annual European Congress; October 24, 2007. [abstract] Value Health. 2007 Nov; 10(6):A381.
Earnshaw SR. Pharmacoeconomics and decision analysis. Presented at the North Carolina State University; November 2007.
Zyczynski TM, Beard SM, Earnshaw SR, McDade CL. Cost-effectiveness analysis of the use of iodixanol compared to iohexol in the United Kingdom. Poster presented at the 2007 ISPOR 10th Annual European Congress; October 24, 2007.
Earnshaw SR, Wilson MR, Blanchette C. Cost-effectiveness of salmeterol/fluticasone propionate in the treatment of COPD: estimating the annual number of exacerbations in chronic obstructive pulmonary disease. Poster presented at the Annual Meeting of the American College of Chest Physicians; October 2007.
Earnshaw SR, Graham CN, Ettinger B, Amonkar MM, Lynch NO, Middelhoven H. Cost-effectiveness of bisphosphonate therapies for women with postmenopausal osteoporosis: implications of improved persistence with less frequently administered oral bisphosphonates. Curr Med Res Opin. 2007 Oct 1;23(10):2517-29.
Earnshaw SR, Hicks K, Richter A, Honeycutt A. A linear programming model for allocating HIV prevention funds with state agencies: a pilot study. Health Care Manag Sci. 2007 Sep 1;10(3):239-52.
Earnshaw SR, McDade CL, Mangel AW, Baran RW. Cost-effectiveness of lubiprostone in a managed care population with chronic idiopathic constipation. Poster presented at the 2007 ACG Annual Meeting; September 2007. [abstract] Am J Gastroenterol. 2007 Sep; 102(S2):S449-50.
Earnshaw SR, Graham CN, Gasper S. Cost-effectiveness of anidulafungin therapy in confirmed candidemia and other forms of invasive candidiasis. Poster presented at the 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); September 2007.
Earnshaw SR, Moride Y, Rochon S. Cost-effectiveness of pegaptanib compared to photodynamic therapy with verteporfin and to standard care in the treatment of subfoveal wet age-related macular degeneration in Canada. Clin Ther. 2007 Sep 1;29(9):2096-106.
Lynch NO, Earnshaw SR, Graham CN, Patroe V, Boisdron J, Middelhoven H. Ibandronate IV injection is cost-effective in the treatment of UK women with postmenopausal osteoporosis who are intolerant to oral bisphosphonates. Poster presented at the European League Against Rheumatism (EULAR) 2007 Annual European Congress of Rheumatology; June 2007.
Earnshaw SR, Wilson MR, Joshi AV. Cost-effectiveness of recombinant activated factor vii in the treatment of intracerebral hemorrhage over a two-year managed care enrollment period. Poster presented at the 2007 ISPOR 12th Annual International Meeting; May 22, 2007. [abstract] Value Health. 2007 May; 10(2):A182. Previously presented at the 2006 International Stroke Conference.
Earnshaw SR, Okazawa M, Wilson MR, Blanchette C. Estimating the annual number of exacerbations in chronic obstructive pulmonary disease. Poster presented at the International Conference of the American Thoracic Society; May 2007.
Graham CN, Earnshaw SR, Saunders M. Assessing the impact of smoking cessation therapies on a managed care organization's budget using census region and state-specific smoking estimates. Poster presented at the Academy of Managed Care Pharmacy 19th Annual Meeting Showcase; April 14, 2007.
Earnshaw SR, Sikirica V, Roskell NS, Shannon PR, Beard S, Schein J, Doshi D, Janagap C. Economic analysis of short-course levofloxacin versus amoxicillin/clavulanate in treating acute bacterial exacerbations of chronic bronchitis. Poster presented at the Academy of Managed Care Pharmacy 19th Annual Meeting Showcase; April 14, 2007.
Earnshaw SR, Brogan AJ. Markov-model toolkit: concepts and assumptions. Presented at the 19th Annual Meeting and Showcase of the Academy of Managed Care Pharmacy; April 2007. San Diego, CA.
Bell C, Graham JB, Earnshaw S, Oleen-Burkey MK, Castelli-Haley J, Johnson K. Cost-effectiveness of four immunomodulatory therapies for relapsing-remitting multiple sclerosis: a Markov model based on long-term clinical data. J Manag Care Pharm. 2007 Apr 1;13(3):245-61.
Lynch NO, Earnshaw SR, Graham CN, Middelhoven H. Cost-effectiveness of ibandronate injection IV in the treatment of UK women with postmenopausal osteoporosis who are intolerant to oral bisphosphonates. Poster presented at the Seventh European Congress on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ECCEO); March 2007.
Pignone M, Earnshaw S, Pletcher MJ, Tice JA. Aspirin for the primary prevention of cardiovascular disease in women: a cost-utility analysis. Arch Intern Med. 2007 Feb 12;167(3):290-5.
Earnshaw SR, Wilson M, Joshi AV. The effect of recombinant activated factor VII in the treatment of intracerebral hemorrhage on health plan budgets. Managed Care Interface. 2007 Jan 1;19(11):39-45.
Earnshaw SR, Beard SM, Gaffney L, Krishnan A, Hogue SL. The impact of premature discontinuation of antidepressant therapy in major depressive disorder in the UK. Poster presented at the 2004 ISPOR 7th Annual European Congress; October 24, 2004. [abstract] Value Health. 2004 Nov; 7(6):A779.
Earnshaw SR, Krishnan A, Hogue SL, Williams JW. The impact of premature discontinuation of antidepressant therapy in major depressive disorder. Poster presented at the 2004 ISPOR 9th Annual International Meeting; May 16, 2004. Arlington, VA. [abstract] Value Health. 2004 May; 7(3):267.
Beard SM, Davies LM, Earnshaw SR, Payne K. Quality and validation standards in healthcare modeling. Poster presented at the International Society for Pharmacoeconomics and Outcomes Research; May 2004.
Pignone M, Earnshaw S, Tice JA, Pletcher M, Wilson M. Aspirin, statins, or both therapies for primary prevention of myccardial infarction: a cost-utility analysis. J Gen Intern Med. 2004 Jan 1;19:121.